Hispolon reduces mitochondrial dysfunction and improves fibrosis of diabetes nephropathy by activating AMPK signal and inhibiting mPTP opening
Cellular Signalling · 2025
DOI: 10.1016/j.cellsig.2025.112130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2025. Verfasst von Yapeng Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Ningxia Medical University, Ningxia, China; Department of Basic Science, Faculty of Health Sciences, University Teknologi MARA, Pu…. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Mitochondria, Signal Transduction, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Natural Science Foundation of Ningxia Province, Ningxia Medical University.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetic nephropathy progression is linked to the AMPK/SIRT1/PGC-1α signaling pathway. Hispolon's potential in improving mitochondrial function and treating diabetic nephropathy via this pathway was unclear. This study used db/db mice and high glucose-induced SV40 MES 13 cells to explore Hispolon's renoprotective mechanisms. In vivo, db/db mice showed glomerular damage, collagen deposition, glycoprotein accumulation, and elevated serum creatinine and urea nitrogen. Hispolon intervention improved these features and parameters. It reduced renal MDA levels, enhanced SOD activity, suppressed pro-inflammatory mediators, and downregulated fibrosis markers. Western blot analysis showed Hispolon restored p-AMPK, SIRT1, and PGC-1α protein levels. In vitro, Hispolon enhanced cell viability, inhibited apoptosis, and reversed high glucose-induced oxidative stress and inflammation in SV40 MES 13 cells. It improved mitochondrial energy metabolism by restoring mitochondrial membrane potential, increasing ATP production, and inhibiting abnormal mPTP opening. Mechanistic studies confirmed that the AMPK/SIRT1/PGC-1α signaling cascade is key for Hispolon's regulation of mPTP dynamics. In conclusion, Hispolon slows diabetic nephropathy progression by activating the AMPK/SIRT1/PGC-1α pathway, inhibiting mPTP opening, and improving mitochondrial dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Nursing, Ningxia Medical University, Ningxia, China; Department of Basic Science, Faculty of Health Sciences, University Teknologi MARA, Puncak Alam, Selangor Darul Ehsan, Malaysia.
- Department of Basic Science, Faculty of Health Sciences, University Teknologi MARA, Puncak Alam, Selangor Darul Ehsan, Malaysia.
- Department of Emergency Medicine, Traditional Chinese Medicine Hospital of Yinchuan, Ningxia, China.
- Department of Occupational and Environmental Health, School of Public Health, Ningxia Medical University, Ningxia, China.
- Department of Acupuncture-Moxibustion and Tuina, People's Hospital of Ningxia Hui Autonomous Region, Ningxia, China.
- Department of Pathology, General Hospital of Ningxia Medical University, Ningxia, China. Electronic address: docwang1715@nxmu.edu.cn.
Förderung
- Natural Science Foundation of Ningxia Province
- Ningxia Medical University
Zitieren
APA
Wang, Y., Danis, A., Wang, X., Ren, J., Ma, T., & Wang, R. (2025). Hispolon reduces mitochondrial dysfunction and improves fibrosis of diabetes nephropathy by activating AMPK signal and inhibiting mPTP opening. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112130
Vancouver
Wang Y, Danis A, Wang X, Ren J, Ma T, Wang R. Hispolon reduces mitochondrial dysfunction and improves fibrosis of diabetes nephropathy by activating AMPK signal and inhibiting mPTP opening. Cellular Signalling. 2025. doi:10.1016/j.cellsig.2025.112130
BibTeX
@article{Wang2025,
author = {Wang, Yapeng and Danis, Ajau and Wang, Xueyi and Ren, Jia and Ma, Teng and Wang, Ruixiao},
title = {Hispolon reduces mitochondrial dysfunction and improves fibrosis of diabetes nephropathy by activating AMPK signal and inhibiting mPTP opening},
journal = {Cellular Signalling},
year = {2025},
doi = {10.1016/j.cellsig.2025.112130}
}
EUVIMED